+13.2% · 90d
$7.44
-0.10 (-1.33%)
News
(1)April 2026
PUMA BIOTECHNOLOGY, INC. — PRE 14A Filing
PBYIPUMA BIOTECHNOLOGY, INC.
# 🧾 What This Document Is This is a **preliminary proxy statement (PRE 14A)** for Puma Biotechnology. It’s like an "information packet and ballot" sent to shareholders before the annual meeting. Its job is to explain what will be voted on and provide the details shareholders need to make informed d
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%